Kura Oncology, Inc. (NASDAQ:KURA) Receives Average Rating of “Moderate Buy” from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has earned an average recommendation of “Moderate Buy” from the seven research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $25.93.

Several research firms recently commented on KURA. StockNews.com started coverage on shares of Kura Oncology in a research report on Thursday, August 17th. They issued a “sell” rating on the stock. Bank of America began coverage on shares of Kura Oncology in a report on Friday, August 11th. They set a “buy” rating and a $31.00 price objective on the stock. Stifel Nicolaus increased their price objective on shares of Kura Oncology from $24.00 to $25.00 in a report on Monday, June 12th. Scotiabank began coverage on shares of Kura Oncology in a research report on Thursday, July 27th. They set a “sector perform” rating and a $10.50 target price for the company. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $30.00 price objective on shares of Kura Oncology in a research report on Thursday, September 7th.

Kura Oncology Trading Down 3.0 %

Shares of NASDAQ:KURA opened at $9.59 on Tuesday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 20.32 and a current ratio of 20.32. Kura Oncology has a twelve month low of $9.28 and a twelve month high of $17.27. The firm has a 50 day simple moving average of $10.37 and a 200-day simple moving average of $11.25.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings data on Thursday, August 3rd. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.04. On average, research analysts expect that Kura Oncology will post -2.18 EPS for the current year.

Institutional Investors Weigh In On Kura Oncology

Hedge funds have recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC lifted its stake in Kura Oncology by 147.3% in the first quarter. Nisa Investment Advisors LLC now owns 2,325 shares of the company’s stock valued at $28,000 after buying an additional 1,385 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Kura Oncology by 386.2% in the first quarter. Allspring Global Investments Holdings LLC now owns 4,089 shares of the company’s stock valued at $50,000 after buying an additional 3,248 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in Kura Oncology by 46.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,710 shares of the company’s stock valued at $50,000 after buying an additional 1,501 shares during the last quarter. Royal Bank of Canada lifted its stake in Kura Oncology by 81.5% in the second quarter. Royal Bank of Canada now owns 6,801 shares of the company’s stock valued at $72,000 after buying an additional 3,053 shares during the last quarter. Finally, Denali Advisors LLC lifted its stake in Kura Oncology by 136.8% in the first quarter. Denali Advisors LLC now owns 9,000 shares of the company’s stock valued at $110,000 after buying an additional 5,200 shares during the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; and tipifarnib, an orally bioavailable inhibitor of farnesyl transferase for the treatment of solid tumors and hematologic indications.